Neurochemistry of dementia

establishing the links.

P. J. Whitehouse, P. Gambetti, S. I. Harik, R. N. Kalaria, G. Perry, Steven G Younkin, M. Tabaton, J. R. Unnerstall

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Neurochemical research in dementia needs to move beyond descriptive inventories of neurotransmitter systems affected in the specific disorders and to link to molecular studies of mechanism and clinical studies of cognition. New advances in Alzheimer's Disease (AD), Huntington's Disease (HD), and Parkinson's Disease (PD) are being guided by models of how nerve cells die in these disorders. Theories of pathophysiology which address the cellular level need to explain the selective vulnerability of neuronal populations in the different diseases. Clinically, the importance of neurochemical studies will be increased by understanding the bridges between neural and cognitive processes. Clinicians are concerned about the nosology of dementias, diagnostic tests, and more effective therapies. The value of neurochemical studies will be enhanced to the extent that they can contribute to understanding and modifying the clinical phenomenology of these disorders. In this paper, we will briefly review what is known about the neurochemistry of dementia but focus most of our attention on establishing the linkage between this level of description and the levels of description which are either "downstream" (molecular biology) or "upstream" (cognition) in terms of a reductionistic conception of understanding the disease process. We will explore how understanding neurochemistry relates to our understanding of disease mechanism and what constraints neurochemical studies place on understanding clinical aspects of disease. We will conclude by briefly discussing some of the problems with our current understanding of the neurochemistry of dementia and how we can address those problems in the future.

Original languageEnglish (US)
Pages (from-to)131-142
Number of pages12
JournalProgress in Clinical and Biological Research
Volume317
StatePublished - 1989
Externally publishedYes

Fingerprint

Neurochemistry
Dementia
Cognition
Huntington Disease
Routine Diagnostic Tests
Neurotransmitter Agents
Parkinson Disease
Molecular Biology
Alzheimer Disease
Neurons
Equipment and Supplies
Research
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Whitehouse, P. J., Gambetti, P., Harik, S. I., Kalaria, R. N., Perry, G., Younkin, S. G., ... Unnerstall, J. R. (1989). Neurochemistry of dementia: establishing the links. Progress in Clinical and Biological Research, 317, 131-142.

Neurochemistry of dementia : establishing the links. / Whitehouse, P. J.; Gambetti, P.; Harik, S. I.; Kalaria, R. N.; Perry, G.; Younkin, Steven G; Tabaton, M.; Unnerstall, J. R.

In: Progress in Clinical and Biological Research, Vol. 317, 1989, p. 131-142.

Research output: Contribution to journalArticle

Whitehouse, PJ, Gambetti, P, Harik, SI, Kalaria, RN, Perry, G, Younkin, SG, Tabaton, M & Unnerstall, JR 1989, 'Neurochemistry of dementia: establishing the links.', Progress in Clinical and Biological Research, vol. 317, pp. 131-142.
Whitehouse PJ, Gambetti P, Harik SI, Kalaria RN, Perry G, Younkin SG et al. Neurochemistry of dementia: establishing the links. Progress in Clinical and Biological Research. 1989;317:131-142.
Whitehouse, P. J. ; Gambetti, P. ; Harik, S. I. ; Kalaria, R. N. ; Perry, G. ; Younkin, Steven G ; Tabaton, M. ; Unnerstall, J. R. / Neurochemistry of dementia : establishing the links. In: Progress in Clinical and Biological Research. 1989 ; Vol. 317. pp. 131-142.
@article{77c64591da9242b9bbedf0bd354e5e96,
title = "Neurochemistry of dementia: establishing the links.",
abstract = "Neurochemical research in dementia needs to move beyond descriptive inventories of neurotransmitter systems affected in the specific disorders and to link to molecular studies of mechanism and clinical studies of cognition. New advances in Alzheimer's Disease (AD), Huntington's Disease (HD), and Parkinson's Disease (PD) are being guided by models of how nerve cells die in these disorders. Theories of pathophysiology which address the cellular level need to explain the selective vulnerability of neuronal populations in the different diseases. Clinically, the importance of neurochemical studies will be increased by understanding the bridges between neural and cognitive processes. Clinicians are concerned about the nosology of dementias, diagnostic tests, and more effective therapies. The value of neurochemical studies will be enhanced to the extent that they can contribute to understanding and modifying the clinical phenomenology of these disorders. In this paper, we will briefly review what is known about the neurochemistry of dementia but focus most of our attention on establishing the linkage between this level of description and the levels of description which are either {"}downstream{"} (molecular biology) or {"}upstream{"} (cognition) in terms of a reductionistic conception of understanding the disease process. We will explore how understanding neurochemistry relates to our understanding of disease mechanism and what constraints neurochemical studies place on understanding clinical aspects of disease. We will conclude by briefly discussing some of the problems with our current understanding of the neurochemistry of dementia and how we can address those problems in the future.",
author = "Whitehouse, {P. J.} and P. Gambetti and Harik, {S. I.} and Kalaria, {R. N.} and G. Perry and Younkin, {Steven G} and M. Tabaton and Unnerstall, {J. R.}",
year = "1989",
language = "English (US)",
volume = "317",
pages = "131--142",
journal = "Progress in Clinical and Biological Research",
issn = "0361-7742",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Neurochemistry of dementia

T2 - establishing the links.

AU - Whitehouse, P. J.

AU - Gambetti, P.

AU - Harik, S. I.

AU - Kalaria, R. N.

AU - Perry, G.

AU - Younkin, Steven G

AU - Tabaton, M.

AU - Unnerstall, J. R.

PY - 1989

Y1 - 1989

N2 - Neurochemical research in dementia needs to move beyond descriptive inventories of neurotransmitter systems affected in the specific disorders and to link to molecular studies of mechanism and clinical studies of cognition. New advances in Alzheimer's Disease (AD), Huntington's Disease (HD), and Parkinson's Disease (PD) are being guided by models of how nerve cells die in these disorders. Theories of pathophysiology which address the cellular level need to explain the selective vulnerability of neuronal populations in the different diseases. Clinically, the importance of neurochemical studies will be increased by understanding the bridges between neural and cognitive processes. Clinicians are concerned about the nosology of dementias, diagnostic tests, and more effective therapies. The value of neurochemical studies will be enhanced to the extent that they can contribute to understanding and modifying the clinical phenomenology of these disorders. In this paper, we will briefly review what is known about the neurochemistry of dementia but focus most of our attention on establishing the linkage between this level of description and the levels of description which are either "downstream" (molecular biology) or "upstream" (cognition) in terms of a reductionistic conception of understanding the disease process. We will explore how understanding neurochemistry relates to our understanding of disease mechanism and what constraints neurochemical studies place on understanding clinical aspects of disease. We will conclude by briefly discussing some of the problems with our current understanding of the neurochemistry of dementia and how we can address those problems in the future.

AB - Neurochemical research in dementia needs to move beyond descriptive inventories of neurotransmitter systems affected in the specific disorders and to link to molecular studies of mechanism and clinical studies of cognition. New advances in Alzheimer's Disease (AD), Huntington's Disease (HD), and Parkinson's Disease (PD) are being guided by models of how nerve cells die in these disorders. Theories of pathophysiology which address the cellular level need to explain the selective vulnerability of neuronal populations in the different diseases. Clinically, the importance of neurochemical studies will be increased by understanding the bridges between neural and cognitive processes. Clinicians are concerned about the nosology of dementias, diagnostic tests, and more effective therapies. The value of neurochemical studies will be enhanced to the extent that they can contribute to understanding and modifying the clinical phenomenology of these disorders. In this paper, we will briefly review what is known about the neurochemistry of dementia but focus most of our attention on establishing the linkage between this level of description and the levels of description which are either "downstream" (molecular biology) or "upstream" (cognition) in terms of a reductionistic conception of understanding the disease process. We will explore how understanding neurochemistry relates to our understanding of disease mechanism and what constraints neurochemical studies place on understanding clinical aspects of disease. We will conclude by briefly discussing some of the problems with our current understanding of the neurochemistry of dementia and how we can address those problems in the future.

UR - http://www.scopus.com/inward/record.url?scp=0024795709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024795709&partnerID=8YFLogxK

M3 - Article

VL - 317

SP - 131

EP - 142

JO - Progress in Clinical and Biological Research

JF - Progress in Clinical and Biological Research

SN - 0361-7742

ER -